Friday, March 31, 2023
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
Nurses - 1.00 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Physician Assistant - 1.00 AAPA hour(s) of Category I credit
This activity was developed for physicians, physician assistants, and nurses involved in primary care, neurology, and internal medicine, or other healthcare providers involved in the diagnosis of patients with Alzheimer disease.
Dementia poses a significant economic burden to healthcare systems and society, with over 50 million people currently affected. Disease progression can take many years and no cure is available. Alzheimer disease (AD) is believed to account for 60% to 80% of dementia cases. The yearly cost of AD and other dementias in the United States is predicted to increase to over $1 trillion by 2050.
AD is a neurodegenerative disease with cognitive, functional, and behavioral impairments. It is characterized by the progressive accumulation of extracellular amyloid beta (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). Up to 30 years ahead of symptoms onset, there may be evidence of AD pathology in the form of Aβ or NFTs, but not of cognitive decline. Early diagnosis can give patients an opportunity to plan ahead. Previous methods of AD diagnosis include postmortem autopsies, costly amyloid positron emission tomography (PET) scans, and unreliable clinical behavioral assessments.
Biomarkers provide a rapid, less expensive, and more quantitative method of diagnosis. Some cerebrospinal fluid (CSF) biomarkers are reliably associated with AD pathology and may provide additional information in clinical diagnosis. Markers such as CSF Aβ42/Aβ40 are concordant with amyloid PET scans and show promise in the detection of AD. Other markers, both CSF and plasma, may also be useful with perspective given to racial disparities and PET concordance.
This educational article will review the neurobiological basis of Alzheimer disease, identify the role of CSF biomarkers in establishing a diagnosis, and discuss racial disparities seen in AD biomarkers.
Upon completion of this activity, participants will be able to:
Educational Review Systems requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Educational Review Systems policies. Others involved in the planning of this activity have no relevant financial relationships.
Jointly provided by Educational Review Systems and Your CE Source.
Your CE Source designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Educational Review Systems has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until March 13, 2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / CE Released: 3/13/2023
Valid for credit through: 3/13/2024
processing....
| « Return to: Pathologies and the Use of Cerebrospinal-Fluid-Based Biomarkers in Alzheimer Disease |
